Pharmacogenomics Market by End-user and Geography - Forecast and Analysis 2022-2026

The pharmacogenomics market share is expected to increase by USD 2.50 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 6.93%.

This pharmacogenomics market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers pharmacogenomics market segmentation by end-user (hospitals and clinics, research organizations, and academics) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The pharmacogenomics market report also offers information on several market vendors, including 23andMe Inc., Abbott Laboratories, Admera Health, and ATS GENETECH PVT. LTD., Dynamic DNA Laboratories, geneOmbio Technologies Pvt. Ltd., Illumina Inc., Laboratory Corp. of America Holdings, Mesa Labs Inc., Myriad Genetics Inc., OneOme LLC, OPKO Health Inc., QIAGEN NV, Quest Diagnostics Inc., and Thermo Fisher Scientific Inc. among others.

What will the Pharmacogenomics Market Size be During the Forecast Period?

Download Report Sample to Unlock the Pharmacogenomics Market Size for the Forecast Period and Other Important Statistics

 

Pharmacogenomics Market: Key Drivers, Trends, and Challenges

The rising prevalence of genetic diseases and disorders is notably driving the pharmacogenomics market growth, although factors such as varying regulations on pharmacogenomics testing and research globally may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic's impact on the pharmacogenomics industry. The holistic analysis of the drivers will help deduce end goals and refine marketing strategies to gain a competitive edge.

Key Pharmacogenomics Market Driver

The rising prevalence of genetic diseases and disorders is one of the major drivers impacting the pharmacogenomics market growth. The significant demand for genetic testing products is attributed to prenatal genetic testing procedures. The increasing incidence of disabilities in newborns has increased the adoption of prenatal testing for the timely treatment of manageable genetic disorders and diseases. For instance, according to the CDC, 1 in every 33 babies (about 3%) is born with birth defects in the US every year. Similarly, between 7 million and 9 million babies are born with birth defects globally. Moreover, early disease diagnosis through prenatal testing procedures is largely preferred by parents with inheritable genetic conditions such as autosomal dominant and recessive disorders. For instance, either parent having a gene with an autosomal dominant condition has a 50% chance of inheriting the disorder to their offspring. This creates a necessity among parents to opt for preventive diagnostic procedures such as prenatal genetic testing. 

Key Pharmacogenomics Market Trend

The growing adoption of direct-to-consumer genetic tests in early disease diagnosis is one of the major trends influencing the pharmacogenomics market growth. Growing demand for timely initiation of healthcare treatments and the increasing adoption of preventive approaches for avoiding disease risks have increased the use of direct-to-consumer genetic tests globally. Market vendors such as Quest Diagnostics, Myriad Genetics Inc., and 23andMe Inc. are offering direct-to-consumer pharmacogenomic testing products such as non-invasive DNA tests, which are designed to assess the risks of developing common health conditions such as migraine, autoimmune disorders, lupus, Alzheimer's disease, melanoma, lung cancer, cystic fibrosis, bladder cancer, colorectal cancer, and breast cancer. 

Key Pharmacogenomics Market Challenge

Varying regulations on pharmacogenomics testing and research globally are one of the major challenges impeding the pharmacogenomics market growth. PCR kits and assays used for in vitro pharmacogenomics testing are regulated under the FDA's 21 CFR (Code of Federal Regulations) in the US, whereas the EU IVD Directive (98/79/EC) regulates the use of PCR kits and assays for in vitro testing in Europe. In addition, clinical laboratories using these assays are required to comply with the regulatory requirements related to clinical and analytical validation in sequencing workflow. Results provided to patients by these clinical laboratories are subjected to legal obligations related to the reproducibility of test results and adherence to high standards of specificity and sensitivity. These results need to meet varying compliance requirements of authorities such as the Centers for Medicare and Medicaid Services (CMS) and Clinical Laboratory Improvement Amendments (CLIA) in the US and the EMA in Europe. Such variations in standards among regulatory authorities hinder compliance, thereby threatening the swift business operations of market vendors across countries. Owing to these factors, the global pharmacogenomics market is expected to witness significant growth during the forecast period.

This pharmacogenomics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the global pharmacogenomics market as a part of the global life science tools and services market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the pharmacogenomics market during the forecast period.

Who are the Major Pharmacogenomics Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

• 23andMe Inc.
• Abbott Laboratories
• Admera Health
• ATS GENETECH PVT. LTD.
• Dynamic DNA Laboratories
• geneOmbio Technologies Pvt. Ltd.
• Illumina Inc.
• Laboratory Corp. of America Holdings
• Mesa Labs Inc.
• Myriad Genetics Inc.
• OneOme LLC
• OPKO Health Inc.
• QIAGEN NV
• Quest Diagnostics Inc.
• Thermo Fisher Scientific Inc.

 

This statistical study of the pharmacogenomics market encompasses successful business strategies deployed by the key vendors. The pharmacogenomics market is concentrated and the vendors are deploying organic and inorganic growth strategies to compete in the market.

To make the most of the opportunities and recover from the post-COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The pharmacogenomics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the leading companies' production, sustainability, and prospects.

Pharmacogenomics Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the pharmacogenomics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Pharmacogenomics Market?

For more insights on the market share of various regions Request PDF Sample now!

39% of the market’s growth will originate from North America during the forecast period. US and Canada are the key markets for the pharmacogenomics market in North America. Market growth in this region will be faster than the growth of the market in other regions.

Growing concerns about early disease diagnosis, a significant rise in commercial approvals for advanced pharmacogenomics products, and the increasing use of pharmacogenomic testing will facilitate the pharmacogenomics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020 and 2021, the COVID-19 outbreak increased the demand for pharmacogenomics, as PCR tests were performed to identify the presence of the virus in the vulnerable population. However, owing to a decline in visits to diagnostic labs and hospitals due to the imposition of a stay-at-home policy, the demand for pharmacogenomics for other chronic illnesses declined in the first half of 2021. 

What are the Revenue-generating End-user Segments in the Pharmacogenomics Market?

To gain further insights on the market contribution of various segments Request a PDF Sample

The pharmacogenomics market share growth in the hospitals and clinics segment will be significant during the forecast period. The rising awareness of early disease diagnosis has created a shift from responsive to preventive care practices. This has increased the demand for predictive diagnostic testing among individuals.

This report provides an accurate prediction of the contribution of all the segments to the growth of the pharmacogenomics market size and actionable market insights on the post-COVID-19 impact on each segment.

 

Pharmacogenomics Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 6.93%
Market growth 2022-2026	$2.50 billion
Market structure	Concentrated
YoY growth (%)	6.11
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 39%
Key consumer countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	23andMe Inc., Abbott Laboratories, Admera Health, ATS GENETECH PVT. LTD., Dynamic DNA Laboratories, geneOmbio Technologies Pvt. Ltd., Illumina Inc., Laboratory Corp. of America Holdings, Mesa Labs Inc., Myriad Genetics Inc., OneOme LLC, OPKO Health Inc., QIAGEN NV, Quest Diagnostics Inc., and Thermo Fisher Scientific Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this Pharmacogenomics Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive pharmacogenomics market growth during the next five years
• Precise estimation of the pharmacogenomics market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the pharmacogenomics industry across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of pharmacogenomics market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch